Loading…
← CockpitCompetitor Analysis › 1187.HK Cofoe Medical Technology Co. Ltd. Class HOpen in the cockpit ↗

Cofoe Medical Technology Co. Ltd. Class H1187.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum strong 65
Mkt cap
$836M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$574,822
20-day average traded
Fwd P/E
13.1×
forward earnings
ROIC−WACC
+4.5 pp
WACC 8.1%
Hurdle
-13 pp
Req g minus delivered
Next earnings
167 days
4 May 2027
Close · HKDHK$29.00
1D-2.4%
1W+7.8%
1M+2.5%
3M-8.3%
6M-10.6%
YTDn/a
1Yn/a
ATR %5.0%
52w lowhigh29.3% off high

What Cofoe Medical Technology does

Employees: 5,081

Cofoe Medical Technology at a glance

Size Cofoe Medical Technology (1187.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $836M, the 624th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$29.00 on 18 Nov 2026.

Performance Over six months the shares fell 10.6%, against -13.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 40.2% over the last twelve months (peer median +6.2%); the operating margin is 9.9% (peer median 10.2%).

Valuation It trades at 13.1× forward earnings against a peer median of 22.4× (5th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.5 points above its cost of capital (8.1% WACC).

Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20261187.HK 91Peer median 87
Six months, rebased to 100: Cofoe Medical Technology against the median of its 20 peers (local-currency closes).

Cofoe Medical Technology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$4.75BHK$3.66BHK$3.23BHK$3.14BHK$3.45B
Revenue growth—+13%+3%-9%—
Gross profitHK$2.69BHK$1.79BHK$1.54BHK$1.24BHK$1.27B
EBITDAn/aHK$573MHK$532MHK$405MHK$437M
Net incomeHK$472MHK$403MHK$338MHK$281MHK$351M
Free cash flowHK$297MHK$604MHK$604MHK$70.9M-HK$555M
Capital expenditureHK$163MHK$193MHK$131MHK$412MHK$744M
Total debtHK$1.56BHK$1.02BHK$1.07BHK$820MHK$648M

Quarterly statements and history in the cockpit →

Cofoe Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%+10%6033673600KIDS688805301602688068688656MCAPAMS002658096530688277688626688767688575SETLBVSBBNXMLAB1187.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Cofoe Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×6033673600688656MCAPAMS002658688626688767688575BVSMLAB1187.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cofoe Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6033673600688805301602688656MCAPAMS002658096530688575301580BVSMLAB1187.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cofoe Medical Technology is the large dot.

Cofoe Medical Technology competitors and peer comparison

How Cofoe Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cofoe Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure1187.HKPeer medianRank in peer set
1-month return+2.5%-8.0%4th highest of 21
6-month return-10.6%-13.2%9th highest of 21
Distance from 52-week high-29.3%-41.9%8th highest of 21
Revenue growth (TTM)+40.2%+6.2%3rd highest of 21
Operating margin9.9%10.2%10th lowest of 21
Forward P/E13.1×22.4×5th cheapest of 14
Growth the price implies (Req g, 7 yrs)-6.4%11.1%4th least demanding of 14
Growth delivered (Del g)+6.6%+12.4%5th lowest of 14
Hurdle (Req g minus delivered)-13.0 pp-1.4 pp4th least demanding of 14
ROIC minus cost of capital+4.5 pp-0.0 pp6th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%

Questions

Which companies are Cofoe Medical Technology's closest peers?
The cockpit's peer set: Cisen Pharmaceutical (603367.SS), Modern Dental (3600.HK), OrthoPediatrics (KIDS), Ningbo Jansen Superconducting Technologies (688805.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ), Beijing Hotgen Biotech (688068.SS), HOB Biotech (688656.SS), MedCap (MCAP.ST).
Is Cofoe Medical Technology expensive compared with its peers?
On forward p/e it trades at 13.1× against a peer median of 22.4×, 5th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Cofoe Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -10.6% against -13.2% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.